Following Merger with Idera Pharmaceuticals, Aceragen Cuts Costs, Slashes 80% of Headcount By Alex KeownMay 8, 2023 Rare disease company Aceragen Inc. is cutting 80% of its staff months after [….]
Cellicon Valley companies closed out 2022 with a roar. Madrigal Pharmaceuticals announced a breakthrough in NASH that could result in the first-approved drug for that disease. Galera Therapeutics closed out December with plans to seek approval for its severe oral mucositis therapy.
According to the recent Life Sciences Research Outlook & Cluster Rankings report from JLL, the Greater Philadelphia region has advanced four positions in the Life Sciences Cluster Composition Matrix, which measures how each market stacks up in terms of human and physical capital. The regional improvement was due to increased and steady funding supporting the specialization of cell and gene therapy research being conducted in the area, which comes as no surprise as these therapies continue to become increasingly important options in disease treatment.
